MedTrace Logo

Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)

NCT02314923 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 513

Last updated 2020-02-05

Study results available
· View outcomes & findings →

Summary

Ebola virus has infected and killed people, mostly in Africa. In 2014, the Ebola virus has affected several thousand people. There is no approved effective way to treat or prevent Ebola. Researchers are trying to develop a vaccine for it. This is a study of the anti-Ebola vaccine BPSC-1001 to see if it is safe and to see how it affects people's immune system.

Conditions

  • Ebola Virus

Interventions

BIOLOGICAL

V920 Vaccine

Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10\^3, 3x10\^4, 3x10\^5, 3x10\^6, 9x10\^6, 2x10\^7, or 1x10\^8 pfu.

OTHER

Placebo

0.9% Saline

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-05
Primary Completion
2016-06-23
Completion
2016-06-23

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02314923 on ClinicalTrials.gov